menu
    • menu

    Company profile for Novaremed

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Novaremed AG is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain. Its fully-owned subsidiary, Novaremed Ltd. was founded in Israel in 2008, where a successful Phase IIa Proof of Concept (PoC) study in Diabetic Neuropathic Pain (DNP) was completed. In 2017, Novaremed AG was incorporated in Basel, Switzerl...
    Novaremed AG is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain. Its fully-owned subsidiary, Novaremed Ltd. was founded in Israel in 2008, where a successful Phase IIa Proof of Concept (PoC) study in Diabetic Neuropathic Pain (DNP) was completed. In 2017, Novaremed AG was incorporated in Basel, Switzerland, which is one of the most important biotech and pharma clusters in Europe to gain access to experienced clinical development staff and investor capital.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NovaremedSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Teichgaesslein 9, 4058 Basel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novaremed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novaremed Completes NIH-Funded Ph 2b for Non-Opioid Nispomeben
    Novaremed Completes NIH-Funded Ph 2b for Non-Opioid Nispomeben

    02 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/02/3142335/0/en/Novaremed-Announces-Completion-of-All-Patient-Visits-in-NIH-Funded-Phase-2b-Trial-of-Non-Opioid-Nispomeben-for-Treating-Chronic-Pain-Associated-with-Diabetic-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    02 Sep 2025
    Share Share
    Novaremed Completes Enrollment in NIH Phase 2b Study
    Novaremed Completes Enrollment in NIH Phase 2b Study

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/06/3074670/0/en/Novaremed-Announces-Completion-of-Enrollment-in-NIH-sponsored-Phase-2b-Study-with-Non-opioid-NRD-E1-for-the-Treatment-of-Chronic-Pain-Associated-with-Diabetic-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront
    Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront

    21 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220721005391/en

    BUSINESSWIRE
    21 Jul 2022
    Share Share
    Novaremed Announces Publication of PI/IIa Study Data With NRD.E1
    Novaremed Announces Publication of PI/IIa Study Data With NRD.E1

    23 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220623005585/en

    BUSINESSWIRE
    23 Jun 2022
    Share Share
    Novaremed’s Non-opioid Lead Drug, NRD.E1, to be Tested in NIH HEAL Phase 2 Trial
    Novaremed’s Non-opioid Lead Drug, NRD.E1, to be Tested in NIH HEAL Phase 2 Trial

    21 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211221005476/en

    BUSINESSWIRE
    21 Dec 2021
    Share Share
    Novaremed Expands its Portfolio of Non-Opioid Treatment Candidates
    Novaremed Expands its Portfolio of Non-Opioid Treatment Candidates

    07 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210907005593/es

    BUSINESSWIRE
    07 Sep 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search